<?xml version="1.0" ?>
<document id="2c0c7b9bdc81461fbf533ae6b89fd78326651306">
  <chunk id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c0" text="Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes"/>
  <chunk id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c1" text="Background: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based antiretroviral vaccination of mice against Friend retrovirus (FV) or HIV."/>
  <chunk id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2" text="Results: Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination with vectors encoding IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα9 or IFNβ. Only the co-administration of adenoviral vectors encoding IFNα2, IFNα4, IFNα6 and IFNα9 resulted in strongly improved immune protection of vaccinated mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral loads. The level of protection correlated with augmented virus-specific CD4 + T cell responses and enhanced antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4 + T cell responses were enhanced by IFNα subtypes. Conclusions: Our results indicate that certain IFNα subtypes have the potential to improve the protective effect of adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4 + T cell and antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of antiretroviral vaccines.">
    <entity charOffset="411-423" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e0" ontology_id="HP_0001744" text="splenomegaly" type="phenotype"/>
    <entity charOffset="550-558" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e1" ontology_id="GO_0003823" text="antibody" type="gene_function"/>
    <entity charOffset="550-558" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e2" ontology_id="GO_0042571" text="antibody" type="gene_function"/>
    <entity charOffset="1039-1047" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e3" ontology_id="GO_0003823" text="antibody" type="gene_function"/>
    <entity charOffset="1039-1047" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e4" ontology_id="GO_0042571" text="antibody" type="gene_function"/>
    <pair e1="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e0" e2="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e1" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.p0" relation="true"/>
    <pair e1="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e0" e2="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e2" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.p1" relation="true"/>
    <pair e1="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e0" e2="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e3" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.p2" relation="true"/>
    <pair e1="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e0" e2="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.e4" id="2c0c7b9bdc81461fbf533ae6b89fd78326651306.c2.p3" relation="true"/>
  </chunk>
</document>
